开云app官网登录入口网页版-官方正版

#ASH年会#

8篇内容 | 850人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1950151, encodeId=af1119501512f, content=<a href='/topic/show?id=b5e2285951' target=_blank style='color:#2F92EE;'>#ASH年会#</a>, objectTitle=亚盛医药抗耐药白血病新药HQP1351临床进展再获ASH年会口头报告，并荣膺“更佳研究”提名, objectType=article, longId=184648, objectId=db8b184648d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db8b184648d7, replyNumber=0, likeNumber=80, createdTime=2020-10-11, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db8b184648d7, moduleTitle=亚盛医药抗耐药白血病新药HQP1351临床进展再获ASH年会口头报告，并荣膺“更佳研究”提名, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=db8b184648d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1950147, encodeId=0a44195014e18, content=<a href='/topic/show?id=b5e2285951' target=_blank style='color:#2F92EE;'>#ASH年会#</a>, objectTitle=2018年ASH年会：Darzalex显著降低初治型多发性骨髓瘤患者的疾病进展风险和死亡率, objectType=article, longId=155285, objectId=2ea6155285c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ea6155285c7, replyNumber=0, likeNumber=96, createdTime=2019-01-01, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ea6155285c7, moduleTitle=2018年ASH年会：Darzalex显著降低初治型多发性骨髓瘤患者的疾病进展风险和死亡率, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2ea6155285c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1950150, encodeId=6c7419501509b, content=<a href='/topic/show?id=b5e2285951' target=_blank style='color:#2F92EE;'>#ASH年会#</a>, objectTitle=2018年ASH年会：KTE-X19治疗成人复发难治急性淋巴细胞白血病患者的全新结果, objectType=article, longId=155289, objectId=eab415528991, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eab415528991, replyNumber=0, likeNumber=71, createdTime=2019-03-21, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eab415528991, moduleTitle=2018年ASH年会：KTE-X19治疗成人复发难治急性淋巴细胞白血病患者的全新结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=eab415528991)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1950148, encodeId=1e74195014892, content=<a href='/topic/show?id=b5e2285951' target=_blank style='color:#2F92EE;'>#ASH年会#</a>, objectTitle=2018年ASH年会：CYAD-01治疗恶性血液肿瘤的新近进展, objectType=article, longId=155286, objectId=8dd815528642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dd815528642, replyNumber=0, likeNumber=74, createdTime=2019-02-26, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dd815528642, moduleTitle=2018年ASH年会：CYAD-01治疗恶性血液肿瘤的新近进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8dd815528642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1950149, encodeId=a811195014917, content=<a href='/topic/show?id=b5e2285951' target=_blank style='color:#2F92EE;'>#ASH年会#</a>, objectTitle=2018年ASH年会：LentiGlobin基因疗法治疗镰刀型红血球疾病的全新数据, objectType=article, longId=155287, objectId=ae7715528ec8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae7715528ec8, replyNumber=0, likeNumber=67, createdTime=2019-08-29, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae7715528ec8, moduleTitle=2018年ASH年会：LentiGlobin基因疗法治疗镰刀型红血球疾病的全新数据, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ae7715528ec8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1950146, encodeId=75331950146b5, content=<a href='/topic/show?id=b5e2285951' target=_blank style='color:#2F92EE;'>#ASH年会#</a>, objectTitle=科济生物在2018ASH年会发布CAR-BCMA-T研究结果, objectType=article, longId=155134, objectId=d16515513478, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16515513478, replyNumber=0, likeNumber=86, createdTime=2019-06-24, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16515513478, moduleTitle=科济生物在2018ASH年会发布CAR-BCMA-T研究结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d16515513478)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1950145, encodeId=e1e619501452c, content=<a href='/topic/show?id=b5e2285951' target=_blank style='color:#2F92EE;'>#ASH年会#</a>, objectTitle=药华医药将于ASH年会发表治疗PV新药Proud-PV三期临床试验结果, objectType=article, longId=83296, objectId=dcc38329618, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcc38329618, replyNumber=0, likeNumber=74, createdTime=2017-07-15, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcc38329618, moduleTitle=药华医药将于ASH年会发表治疗PV新药Proud-PV三期临床试验结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dcc38329618)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1950144, encodeId=f8141950144f8, content=<a href='/topic/show?id=b5e2285951' target=_blank style='color:#2F92EE;'>#ASH年会#</a>, objectTitle=第53届ASH年会 AML临床研究新近进展, objectType=article, longId=3841, objectId=eb743841af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb743841af, replyNumber=0, likeNumber=76, createdTime=2012-06-30, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb743841af, moduleTitle=第53届ASH年会 AML临床研究新近进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=eb743841af)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

ASH年会

2020-05-29

xjy02 (审核中...)

前往app查看评论内容

#ASH年会#

亚盛医药抗耐药白血病新药HQP1351临床进展再获ASH年会口头报告，并荣膺“更佳研究”提名

2020-10-11

xjy02 (审核中...)

前往app查看评论内容

#ASH年会#

2018年ASH年会：Darzalex显著降低初治型多发性骨髓瘤患者的疾病进展风险和死亡率

2019-01-01

xjy02 (审核中...)

前往app查看评论内容

#ASH年会#

2018年ASH年会：KTE-X19治疗成人复发难治急性淋巴细胞白血病患者的全新结果

2019-03-21

xjy02 (审核中...)

前往app查看评论内容

#ASH年会#

2018年ASH年会：CYAD-01治疗恶性血液肿瘤的新近进展

2019-02-26

xjy02 (审核中...)

前往app查看评论内容

#ASH年会#

2018年ASH年会：LentiGlobin基因疗法治疗镰刀型红血球疾病的全新数据

2019-08-29

xjy02 (审核中...)

前往app查看评论内容

#ASH年会#

科济生物在2018ASH年会发布CAR-BCMA-T研究结果

2019-06-24

xjy02 (审核中...)

前往app查看评论内容

#ASH年会#

药华医药将于ASH年会发表治疗PV新药Proud-PV三期临床试验结果

2017-07-15

xjy02 (审核中...)

前往app查看评论内容

#ASH年会#

第53届ASH年会 AML临床研究新近进展

2012-06-30

科室
- - 订阅+
  - 更多科室
工具
服务